
Botulinum toxin type A, which includes Botox and Dysport, was the top non-surgical cosmetic procedure of 2010, according to recent stats from the American Society of Plastic Surgeons (ASPS). These injectables have proven their popularity and effectiveness as wrinkle fillers, and the companies that make them continue to look to expand their usage.
A CBS Interactive Business Network report gives an update on what the future may hold for these products. Medicis, maker of Dysport, is working with a company called Revance to create a wipe-on, wipe-off version of botulinum toxin to treat facial wrinkles and excessive sweating.
Meanwhile Allergan, maker of Botox, is researching the drug for several uses, which include as a painkiller and a treatment for juvenile cerebral palsy and enlarged prostate.
Allergan also continues to focus on Botox’s huge success as a wrinkle filler with a new website that allows users to upload their own photos. Then they can manipulate the image to see what they might look like after Botox (pictured in this post is an example of a before and after image from the website).
Botox was also approved in October 2010 as a preventive treatment for chronic migraine.
The CBS report says sales of Allergan’s Botox began recovering last year after declining during the recession, and ASPS statistics show that cosmetic minimally-invasive procedures increased 5 percent in 2010 from 2009.
Dysport, which was released by Medicis in 2009, has also seen sales success. The company’s non-acne skin products were up 31 percent in 2010, and most of that increase was attributed to Dysport.
Dr. Heffernan offers same day appointments for Botox and Dypsort.







